US 12,285,401 B2
Pharmaceutical composition comprising trimebutine or pharmaceutically acceptable salt thereof as an active ingredient for prevention or treatment of cancer
Jun Woo Kim, Daegu (KR); Sang Hyun Min, Daegu (KR); Heejin Lee, Daegu (KR); and Oh Bin Kwon, Daegu (KR)
Assigned to DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION, Daegu (KR)
Appl. No. 17/600,976
Filed by DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION, Daegu (KR)
PCT Filed Apr. 6, 2020, PCT No. PCT/KR2020/004637
§ 371(c)(1), (2) Date Nov. 8, 2021,
PCT Pub. No. WO2020/204678, PCT Pub. Date Oct. 8, 2020.
Claims priority of application No. 10-2019-0039613 (KR), filed on Apr. 4, 2019; and application No. 10-2020-0041000 (KR), filed on Apr. 3, 2020.
Prior Publication US 2022/0193020 A1, Jun. 23, 2022
Int. Cl. A61K 31/24 (2006.01); A23L 33/10 (2016.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/24 (2013.01) [A23L 33/10 (2016.08); A61K 45/06 (2013.01); A61P 35/00 (2018.01)] 7 Claims
OG exemplary drawing
 
1. A method for treating ovarian cancer comprising administering a compound represented by formula 1 below, a stereoisomer thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof as an active ingredient,
wherein the ovarian cancer is characterized by the presence of ovarian cancer stem cells and the compound is administered in an amount sufficient to inhibit the proliferation of the ovarian cancer stem cells:

OG Complex Work Unit Chemistry